MTCH2

Across TCGA pan-cancer cohorts, MTCH2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTCH2 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MTCH2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTCH2 expression acts as an unfavorable survival marker.

LSCC, PDAC, and LUAD are the cancer types where MTCH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.506	1.000	.004	13	view →
PDAC	DFS	Tertile	All	0.300	0.466	.022	8	view →
LUAD	DFS	Quartile	All	0.448	0.913	.009	5	view →
CCRCC	OS	Median	IV	0.150	0.785	.040	4	view →
UCEC	DFS	Tertile	All	0.779	0.943	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTCH2–LSCC (DFS)

Open the LSCC breakdown →